Volpara (ASX:VHT) share price pushes higher on FY 2021 results

The Volpara Health Technologies Ltd (ASX:VHT) share price is on the move on Thursday following the release of its full year results…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Volpara Health Technologies Ltd (ASX: VHT) share price is pushing higher on Thursday.

At the time of writing, the healthcare technology company's shares are up 1% to $1.26.

A doctor looks unsure.

Image source: Getty images

Why is the Volpara share price pushing higher?

Investors have been buying the company's shares following the release of its full year results for FY 2021.

For the 12 months ending 31 March, Volpara reported record revenue from customer contracts of NZ$19.7 million. This was a 57% increase on the prior corresponding period and driven by a 99% lift in subscription revenue to NZ$18.1 million.

This was driven by further market share gains. Approximately 32% of US women now have a Volpara product applied on their images and data. This compares to 27% at the end of the prior corresponding period.

Another positive was the company's gross margin, which expanded from 86% to 91%. This was driven by several factors, including a focus on cost reductions and scalability of Microsoft Azure, which is its largest cost-of-revenue expense item. Management expects its gross margins to remain within 90% to 92% in FY 2022.

The company's operating costs increased by just 8% during the year to NZ$39 million. Management advised that costs would have been flat excluding the first full year of MRS costs and two months of CRA costs.

This ultimately led to the company reporting a 14% improvement in its net loss to NZ$17.5 million for the year. Pleasingly, Volpara has the balance sheet strength to withstand this loss. At the end of the period, the company's cash balance stood at NZ$32.2 million.

Management commentary

Volpara's CEO and Chief Scientist, Dr Ralph Highnam, said: "FY2021 was an excellent year for Volpara. We successfully conducted our second acquisition, of Boston-based breast cancer risk company CRA Health, LLC, but we've also done a huge amount of work behind the scenes to make the company more scalable: digital marketing through to smarter use of our cloud services through to easier-to-deploy software systems into clinics."

"It's great to see that work start to come through in the numbers as we see Gross Margin moving upwards and the net loss coming down, even as we continue to grow at a strong pace. We look forward with relish to now Accelerating Out of COVID-19 and reporting on those results during FY2022," he added.

Outlook

Management expects its growth to continue in FY 2022. It has provided revenue guidance of approximately NZ$25 million to NZ$26 million. This represents year on year growth of 27% to 32%.

And, as mentioned above, the company is expecting its gross margins to be in the range of 90% to 92% in FY 2022.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends VOLPARA FPO NZ. The Motley Fool Australia has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

a group of business people sit dejectedly around a table, each expressing desolation, sadness and disappointment by holding their head in their hands, casting their gazes down and looking very glum.
Share Fallers

DroneShield shares tumble 17% as CEO exit revives leadership fears

Investors bank gains as DroneShield leadership reset unsettles sentiment...

Read more »

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Domino's and Pro Medicus shares

A leading analyst expects Domino’s and Pro Medicus shares to keep underperforming.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Coles, Endeavour, and Rio Tinto shares

The team at Morgans has given its verdict on these popular shares.

Read more »

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
Broker Notes

Morgans names two ASX 200 shares to buy and one to sell this week

Let's see which shares Morgans is bullish and bearish on this week.

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Broker Notes

Why beaten down CSL shares now offer 'long-term appeal'

A leading expert gives his outlook for CSL’s beaten down shares.

Read more »

A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks
Broker Notes

3 compelling reasons to buy QBE shares today

A top expert forecasts more outperformance from QBE shares.

Read more »

Falling prices of oil demonstrated by a red arrow and barrels of oil.
Energy Shares

ASX shares to watch as oil price crashes

The turnaround in oil prices is a huge headwind for the ASX shares.

Read more »